SEC Form SC 13G filed by Aspira Women's Health Inc.
$AWH
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
(Amendment
No. )*
|
ASPIRA WOMEN'S HEALTH,
INC.
|
|
(Name of
Issuer)
|
|
Common Stock, Par Value $0.001 Per
Share
|
|
(Title of Class of Securities)
|
|
04537Y109
|
|
(CUSIP
Number)
|
|
December 31, 2021
|
|
(Date of event which requires filing of this
statement)
|
Check
the appropriate box to designate the Rule pursuant to which this
Schedule is filed:
☐ Rule
13d-1(b)
☒ Rule
13d-1(c)
☐ Rule
13d-1(d)
*The
remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided
in a prior cover page.
The
information required on the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise
subject to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however, see the
Notes).
Continued on following pages
|
CUSIP No.
04537Y109
|
SCHEDULE
13D
|
Page 2 of 5
Pages
|
|
1
|
NAME OF REPORTING
PERSONS
ROBERT H.
DRYSDALE
|
|||
|
2
|
CHECK THE
APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
☐
(b)
☐
|
|||
|
3
|
SEC USE
ONLY
|
|||
|
4
|
SOURCE OF
FUNDS
United States
|
|||
|
5
|
CHECK BOX IF
DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM
2(d) or 2(e) ☐
|
|||
|
6
|
CITIZENSHIP OR
PLACE OF ORGANIZATION
|
|||
|
NUMBER
OF
|
7
|
SOLE VOTING
POWER
|
6,412,826
|
|
|
SHARES
BENEFICIALLY
|
8
|
SHARED VOTING
POWER
|
0
|
|
|
OWNED
BY
EACH
|
9
|
SOLE DISPOSITIVE
POWER
|
6,412,826
|
|
|
REPORTING
PERSON
WITH
|
10
|
SHARED DISPOSITIVE
POWER
|
0
|
|
|
11
|
AGGREGATE AMOUNT
BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,412,826
|
|||
|
12
|
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES ☐
5.7% (based on 112,126,549
common shares outstanding as of November 8, 2021 per Issuer’s
10-Q).
|
|||
|
13
|
PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW (11)
|
|||
|
14
|
TYPE OF REPORTING
PERSON
IN
|
|||
|
CUSIP No.
04537Y109
|
SCHEDULE
13D
|
Page 3 of 5
Pages
|
ITEM
1(a).
NAME OF
ISSUER
Aspira
Women’s Health, Inc.
ITEM
1(b).
ADDRESS
OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
12117
Bee Caves Road, Building III, Suite 100
Austin,
Texas 78738
ITEM
2(a).
NAME OF
PERSON FILING.
This
Schedule 13G is being filed by Robert H. Drysdale (the
“Reporting Person”).
ITEM2
(b).
ADDRESS
OR PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE.
The
address of the Reporting Person is 132A Royal Circle, Honolulu,
Hawaii 96816.
ITEM
2(c).
CITIZENSHIP.
United
States.
ITEM2
(d).
TITLE
OF CLASS OF SECURITIES:
Common
stock.
ITEM2
(e).
CUSIP
No.
04537Y109
ITEM
3.
IF THIS STATEMENT
IS FILED PURSUANT TO RULES 13D-1(B), OR 13D-2(B):
Not
applicable.
ITEM
4.
OWNERSHIP
(a)
Amount beneficially
owned: 6,412,826
(b)
Percentage of
class: 5.7% (based on 112,126,549 common shares outstanding as of
November 8, 2021 per Issuer’s 10-Q).
(c)
Number
of shares as to which the person has:
(i)
Sole
power to vote or to direct the vote: 6,412,826
(ii)
Shared
power to vote or to direct the vote: 0
(iii)
Sole
power to dispose or to direct the disposition of:
6,412,826
(iv)
Shared power to
dispose or to direct the disposition of: 0
ITEM
5.
OWNERSHIP OF FIVE
PERCENT OR LESS OF A CLASS.
Not
applicable.
|
CUSIP No.
04537Y109
|
SCHEDULE
13D
|
Page 4 of 5
Pages
|
ITEM
6.
OWNERSHIP OF MORE
THAN 5 PERCENT ON BEHALF OF ANOTHER PERSON.
Not
applicable.
ITEM
7.
IDENTIFICATION AND
CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING
REPORTED ON BY THE PARENT HOLDING COMPANY.
Not
applicable.
ITEM
8.
IDENTIFICATION AND
CLASSIFICATION OF MEMBERS OF THE GROUP.
Not
applicable.
ITEM
9.
NOTICE OF
DISSOLUTION OF GROUP.
Not
applicable.
ITEM
10.
CERTIFICATIONS.
By signing below I
certify that, to the best of my knowledge and belief, the
securities referred to above were acquired and are held in the
ordinary course of business and were not acquired and are not held
for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any
transaction having that purpose or effect, or other than activities
solely in connection with a nomination under
§240.14a-11.
|
CUSIP No.
04537Y109
|
SCHEDULE
13D
|
Page 5 of 5
Pages
|
SIGNATURES
After reasonable
inquiry and to the best of my knowledge and belief, I certify that
the information set forth in this statement is true, complete and
correct.
|
|
|
|
|
|
|
|
|
|
|
Dated: February 14,
2022
|
By:
|
/s/ Robert H. Drysdale
|
|
|
|
|
Robert H. Drysdale
|
|
|
|
|
|
|